Pacific Biosciences (PACB -8.70%), a life sciences company specializing in DNA sequencing technology, published its latest earnings results for the fiscal second quarter ended June 30, 2025, on August 7, 2025. The headline news was a revenue figure of $39.8 million (GAAP), which surpassed analyst expectations of$36.62 million. Losses per share (Non-GAAP EPS) were less than predicted at $(0.13), beating the non-GAAP loss of$(0.17) per share that analysts had forecast. Both top- and bottom-line results impr ...